JP2003534282A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003534282A5 JP2003534282A5 JP2001585781A JP2001585781A JP2003534282A5 JP 2003534282 A5 JP2003534282 A5 JP 2003534282A5 JP 2001585781 A JP2001585781 A JP 2001585781A JP 2001585781 A JP2001585781 A JP 2001585781A JP 2003534282 A5 JP2003534282 A5 JP 2003534282A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- use according
- apoptotic
- patient
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000001640 apoptogenic effect Effects 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 11
- 210000000601 blood cell Anatomy 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 5
- 208000033808 peripheral neuropathy Diseases 0.000 description 4
- 239000000463 material Substances 0.000 description 3
- 201000001119 neuropathy Diseases 0.000 description 3
- 230000007823 neuropathy Effects 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 206010034620 Peripheral sensory neuropathy Diseases 0.000 description 1
- 206010036105 Polyneuropathy Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 208000029033 Spinal Cord disease Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010044688 Trisomy 21 Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000036473 myasthenia Effects 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 208000013315 neuromuscular junction disease Diseases 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000007824 polyneuropathy Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 201000005572 sensory peripheral neuropathy Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA 2309424 CA2309424A1 (en) | 2000-05-25 | 2000-05-25 | Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders |
| CA2,309,424 | 2000-05-25 | ||
| PCT/CA2001/000759 WO2001089537A2 (en) | 2000-05-25 | 2001-05-25 | Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003534282A JP2003534282A (ja) | 2003-11-18 |
| JP2003534282A5 true JP2003534282A5 (enExample) | 2008-07-10 |
Family
ID=4166243
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001585781A Withdrawn JP2003534282A (ja) | 2000-05-25 | 2001-05-25 | 神経変性及び他の神経学的疾患の治療における使用のためのアポトーシス体 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US7132285B2 (enExample) |
| EP (1) | EP1289535B1 (enExample) |
| JP (1) | JP2003534282A (enExample) |
| AT (1) | ATE366581T1 (enExample) |
| AU (1) | AU2001261987A1 (enExample) |
| CA (1) | CA2309424A1 (enExample) |
| DE (1) | DE60129322T2 (enExample) |
| DK (1) | DK1289535T3 (enExample) |
| ES (1) | ES2290134T3 (enExample) |
| PT (1) | PT1289535E (enExample) |
| TW (1) | TWI239843B (enExample) |
| WO (1) | WO2001089537A2 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2309518A1 (en) * | 2000-05-25 | 2001-11-25 | Vasogen Ireland Limited | Apoptotic entities for use in treatment of t-cell-mediated and inflammatory disorders |
| TWI281407B (en) * | 2000-09-18 | 2007-05-21 | Vasogen Ireland Ltd | Apoptosis-mimicking synthetic entities and use thereof in medical treatment |
| CA2333494A1 (en) * | 2001-02-01 | 2002-08-01 | Vasogen Ireland Limited | Blood brain barrier modulation |
| EP1429727A1 (en) * | 2001-09-18 | 2004-06-23 | Vasogen Ireland Limited | Apoptosis-mimicking synthetic entities and use thereof in medical treatment |
| US20060008517A1 (en) * | 2004-07-09 | 2006-01-12 | Lynch Marina A | Treatment of age-related memory impairment |
| US11512289B2 (en) | 2015-02-18 | 2022-11-29 | Enlivex Therapeutics Rdo Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11000548B2 (en) | 2015-02-18 | 2021-05-11 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11497767B2 (en) | 2015-02-18 | 2022-11-15 | Enlivex Therapeutics R&D Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11304976B2 (en) | 2015-02-18 | 2022-04-19 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11318163B2 (en) | 2015-02-18 | 2022-05-03 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11596652B2 (en) | 2015-02-18 | 2023-03-07 | Enlivex Therapeutics R&D Ltd | Early apoptotic cells for use in treating sepsis |
| US10857181B2 (en) | 2015-04-21 | 2020-12-08 | Enlivex Therapeutics Ltd | Therapeutic pooled blood apoptotic cell preparations and uses thereof |
| CA3014885A1 (en) | 2016-02-18 | 2017-08-24 | Enlivex Therapeutics Ltd. | Combination immune therapy and cytokine control therapy for cancer treatment |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5980954A (en) * | 1992-02-07 | 1999-11-09 | Vasogen Ireland Limited | Treatment of autoimmune diseases |
| US6696092B2 (en) * | 1992-02-07 | 2004-02-24 | Vasogen Ireland Limited | Endothelial lining effects and treatment of vasospastic disorders |
| ATE219953T1 (de) | 1992-02-07 | 2002-07-15 | Vasogen Inc | Verfahren zur erhöhung den stickoxidkonzentration im blut |
| PT1146885E (pt) * | 1999-01-12 | 2003-10-31 | Vasogen Ireland Ltd | Pre-condicionamento contra a morte celular |
| CA2271190A1 (en) * | 1999-05-06 | 2000-11-06 | Vasogen Ireland Limited | Improved method for treating mammals with modified mammalian blood |
| CN1187507C (zh) | 2000-03-07 | 2005-02-02 | E·F·P·地板制品有限公司 | 嵌板 |
| CA2309417A1 (en) | 2000-05-25 | 2001-11-25 | Anthony E. Bolton | Apoptotic entities for use in treatment of endothelium dysfunction disorders |
| CA2309518A1 (en) | 2000-05-25 | 2001-11-25 | Vasogen Ireland Limited | Apoptotic entities for use in treatment of t-cell-mediated and inflammatory disorders |
| US7122208B2 (en) * | 2001-04-06 | 2006-10-17 | Vasogen Ireland Limited | Compositions containing apoptotic entities |
| EP1469733A4 (en) | 2001-11-29 | 2008-07-23 | Therakos Inc | METHOD FOR PRE-TREATING A PATIENT WITH EXTRACORPORAL PHOTOPHERESIS AND / OR APOPTOTIC CELLS |
| US7255880B2 (en) * | 2003-04-03 | 2007-08-14 | Vasogen Ireland Limited | Treatment of endothelin-related disorders |
-
2000
- 2000-05-25 CA CA 2309424 patent/CA2309424A1/en not_active Abandoned
-
2001
- 2001-05-25 WO PCT/CA2001/000759 patent/WO2001089537A2/en not_active Ceased
- 2001-05-25 DK DK01935897T patent/DK1289535T3/da active
- 2001-05-25 PT PT01935897T patent/PT1289535E/pt unknown
- 2001-05-25 AT AT01935897T patent/ATE366581T1/de not_active IP Right Cessation
- 2001-05-25 ES ES01935897T patent/ES2290134T3/es not_active Expired - Lifetime
- 2001-05-25 AU AU2001261987A patent/AU2001261987A1/en not_active Abandoned
- 2001-05-25 DE DE2001629322 patent/DE60129322T2/de not_active Expired - Fee Related
- 2001-05-25 US US09/871,146 patent/US7132285B2/en not_active Expired - Fee Related
- 2001-05-25 EP EP20010935897 patent/EP1289535B1/en not_active Expired - Lifetime
- 2001-05-25 JP JP2001585781A patent/JP2003534282A/ja not_active Withdrawn
- 2001-06-01 TW TW90113346A patent/TWI239843B/zh not_active IP Right Cessation
-
2006
- 2006-10-17 US US11/583,986 patent/US20070087010A1/en not_active Abandoned
-
2007
- 2007-10-29 US US11/927,094 patent/US20080131416A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003534282A5 (enExample) | ||
| JP4922762B2 (ja) | 速効性でかつ高い吸収性を可能とする経鼻投与用組成物 | |
| CA2118121C (en) | Methods and compositions for the treatment of diseases with interferon while reducing side effects | |
| JP2004522714A5 (enExample) | ||
| FI88108B (fi) | Foerfarande foer framstaellning av en oral, farmaceutisk, fast komposition med prolongered effekt | |
| JPH0725689B2 (ja) | 顆粒球コロニ−刺激因子を含有する徐放性製剤 | |
| FR2798065B1 (fr) | Utilisation de la nicotine ou de ses derives dans un medicament pour le traitement des maladies neurologiques, notamment la maladie de parkinson | |
| HUP0000299A1 (hu) | Késleltetett hatóanyag-leadású gyógyszerkészítmények | |
| JPWO2000047233A1 (ja) | 口腔内で速やかに崩壊する錠剤 | |
| JP2002532432A5 (enExample) | ||
| EP1369119B1 (en) | Il-12 expression controlling agents | |
| WO2004017913A3 (en) | Arginine silicate inositol complex and use thereof | |
| JP2002529097A5 (enExample) | ||
| JP2003534281A5 (enExample) | ||
| JP2002523437A5 (enExample) | ||
| RU2010114050A (ru) | Применение пептида рецептора il-1 индивидуально или в комбинации с октадециловым эфиром d-ala-gln в качестве терапевтического средства | |
| JPH0637395B2 (ja) | ジペプタイド誘導体を含有する、筋萎縮性側索硬化症を治療するための薬剤 | |
| JP2002530353A5 (enExample) | ||
| JP2002544233A5 (enExample) | ||
| KR20150011379A (ko) | 옥시부티닌 투여를 위한 방법 및 조성물 | |
| US20230181847A1 (en) | Product delivery devices and methods | |
| WO2001012214A3 (en) | MYCOPHENOLATE MOFETIL IN ASSOCIATION WITH PEG-IFN-$g(a) | |
| ZA200600027B (en) | Pharmaceutical formulations for intranasal administration of protein comprising a chitosan or a derivative thereof | |
| JP3183378B2 (ja) | ムチン産生促進剤 | |
| JP2002529515A5 (enExample) |